Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590375 | 0.93 | MAPT (0.37) | MAPTSMN1; SMN2ALDH1A1CYP3A4GFER | |
| SCHEMBL4071829 | 0.91 | MAPT (0.35) | MAPTSMN1; SMN2HSD11B1ALDH1A1GFER | |
| Trifluoroacetic Acid SCHEMBL589692 | 0.86 | SMN1; SMN2 (0.33) | MAPTSMN1; SMN2TP53LMNA | |
| SCHEMBL4063471 | 0.84 | CNR1 (0.39) | MAPTSMN1; SMN2HSD11B1GFERLMNA | |
| SCHEMBL589889 | 0.83 | GAA (0.41) | MAPTALDH1A1GFERLMNA | |
| SCHEMBL588890 | 0.82 | MAPT (0.36) | MAPTALDH1A1GFERTSHR | |
| SCHEMBL4071626 | 0.82 | MAPT (0.35) | MAPTGFER | |
| SCHEMBL14394648 | 0.82 | KHK (0.33) | MAPTHSD11B1ALDH1A1GFERL3MBTL1 | |
| SCHEMBL588903 | 0.81 | CNR1 (0.33) | MMP2 | |
| SCHEMBL5273648 | 0.79 | MAPT (0.32) | MAPTALDH1A1GFERLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822474-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | DPYD, DHFR, TPMT | MAPT 2212/4885SMN1; SMN2 833/4885HSD11B1 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.